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INTRODUCTION
Febrile neutropenia is an oncological emergency occurring in patients undergoing chemotherapy for cancer, and is associated with significant morbidity, mortality and high cost of treament. 1 The febrile episode is preceded by a reduction in the absolute neutrophil count (ANC) which comprises of segments, blasts and neutrophils. Even though neutropenia is defined as ANC less than 1.0 x10 9 L cells, this figure is referenced for Caucasians and there is a suggestion that it in blacks it should be less than 1.2 x 10 9 L cells due to mild neutropenia being a normal phenomenon. 2 Febrile neutropenia is defined as a single oral temperature of > 38.3 o C or 38 o C for more than one hour, associated with a significant reduction in granulocyte count (ANC < 0.5 x10 9 L or 1.0 x 10 9 L cells, but predicted to fall to <500cells/ mm 3 ). 1 Mortality rates have reduced from 50 percent in the 1960s to less than 10 percent today due to improved management strategies. 3 Most chemotherapy agents/protocols have the potential of causing febrile neutropenia. Most cause a blood count nadir at 10 to 14 days, but can occur anytime from a few days to about 6 weeks depending on the drug. 1 The relationship between low neutrophil count and the increased risk of infection was published in 1966 by Bodey GP et al. 4 They noted that the major threat of neutropenia is bacterial infection, and the greatest risk was in patients with ANC less than 0.1 x10 9 L cells. Signs and symptoms of infection are however often subtle due to a lack of adequate inflammatory response.
In the absence of an obvious source of infection which occurs in 50%-70% of cases, empiric antibiotic treatment should cover Gram positive bacilli and Gram negative cocci as microbiological evidence of infection occurs in less than 15% of cases. 1 Antibiotic choice however depends on the prevailing local condition such as drug availability, isolated pathogens, risk/ severity of bacterial sepsis, resistance patterns, ease of administration and cost in our environment. Earlier studies have reported a 70 percent mortality if administration of antibiotics (within five hours) is delayed. 5 The use of granulocyte stimulating growth factor (G-CSF) has been repeatedly shown to be effective in prophylaxis and reducing the duration of neutropenia and hospital stay but does not affect mortality. The purpose of this study was to assess the outcome of patients admitted and managed at the Oncology Unit in Accra, Ghana between January 2005 and February 2008. As a developing country we have many limiting resources in the health care system especially for emergency care.
SUBJECTS, MATERIALS, AND METHODS
The medical charts of 20 patients on chemotherapy admitted to the Radiotherapy Centre for febrile neutropenia from Data retrieved included age, sex, type of cancer and number of cycles of chemotherapy taken. Other parameters included initial temperature, site of infection, ANC at presentation and antibiotic choice. Use of antifungal drugs, duration of fever (defined as the number of days lapsed for complete resolution of fever for >24 hours) and overall treatment outcome were also assessed. This retrospective research was conducted in accordance with the Declaration of Helsinki and national and institutional standards. Averages of data are summarised as means or medians.
RESULTS
Of the 20 patients records analyzed, 12(60%) were females and 8(40%) males with a median age of 42 years. (Range 15 to 68 years), and male to female ratio 3:2. Absolute Neutrophil Count (ANC) at presentation ranged from 0 to 0.6x10 9 /L with only one patient having a value greater than 0.5 X 10 9 /L. Eleven (52%) patients had cancers involving the head and neck region comprising nasopharyngeal cancer (n=9) and one case each of tongue and mandible. Breast cancer accounted for seven (35%) of cases and anorectal cancer accounted for two (10%), (Fig 1.) . Eight (40%) patients had Granulocyte Colony Stimulating Factor (G-CSF) during their neutropenic fever episode with an average of three injections per patient (range 1 to 6). Six of them received it after five days of persistent neutropenia and fever. Cost was the major deterrent in the limited use of GCSF.
The mean duration of fever was 4.5 days (Range 1 to 10 days). Patients were discharged home on oral ciprofloxacin and augumentin for ten days when afebrile for 72 hours.
Overall, 18(90%) recovered from their neutropenic episode. Mortality from febrile neutropenia was 2(10%). The two patients who died required a change in antibiotics three consecutive times in addition to antifungal agents.
DISCUSSION
Fever in a patient with neutropenia is a grave condition requiring immediate emergency medical attention to avoid fatality. 6 Several trials have indicated similar outcomes for oral versus intravenous antibiotics to cover both gram negative cocci and gram positive bacilli, however, the advantage of intravenous route cannot be overlooked in gravely ill patients. 7 The increased use of multimodality treatment has increased local control and survival rates as well as increased toxicity, with most serious being febrile neutropenia secondary to anticancer drugs. 8 Dose adjustments to ameliorate this side effect have been shown to be detrimental by reducing survival rates in most cancers. 9, 10 It seems the solution to optimize dose is by use of granulocyte stimulating growth factors which comes at a prohibitive cost to patients in developing countries.
In our institution we realized the high mortality rate when our patients were managed elsewhere in the hospital. The reason for this may be multifactorial. We therefore developed a policy to manage them in our limited inpatient department with one to one nursing care and an isolated ward.
Investigations Recommended for Febrile Neutropenia
Even though it is recommended that all neutropenic patients have immediate full blood count, renal and liver profile, wound swabs, chest X-ray and CT scans, blood, urine and sputum cultures, 11 microbiology laboratory tests were however typically difficult to obtain prior to start of antibiotics as patients traditionally presented on Fridays ,after hours or had limited financial resources. In spite of somewhat suboptimal conditions in developing countries, we are able to manage these cases successfully and present a retrospective study of twenty cases of febrile neutropenia patients who presented to us between 2005 and 2008.
Anticancer Drugs Causing Neutropenia
Several studies including one from Curtin et al have noted high rate of febrile neutropenia in patients receiving cisplatin-based chemotherapy. 12 In our analysis more than half of the patients (n=13) received cisplatin-based chemotherapy for head and neck or anal cancer in combination with continuous infusion of 5-Fluorouracil , explaining the high incidence of oral mucositis. Anthracyclines such as Adriamycin are also associated with increased incidence of Eleven (55%) patients had Cisplatin with 5-fluorouracil with seven patients developing neutropenic fever after the first cycle. Seven (35%) patients received Anthracycline-based chemotherapy, four developed febrile neutropenia after the first cycle. The patient who received Taxane chemotherapy as well as the other who received CMF developed neutropenia after the first cycle. In total 11(55%) developed febrile neutropenia with first cycle and 7(35%) with second cycle. Two(10%) developed febrile neutropenia after three or more cycles. None of the patients had prior chemotherapy. Choice febrile neutropenia. 13 This is consistent with our findings that breast cancer patients receiving Adriamycin made up one-third of the group. Two patients who received relatively less myelosuppressive drugs (paclitaxel, a taxane and CMF) developed neutropenia. This goes to support the saying in oncology that all anticancer drugs have the potential of causing febrile neutropenia and therefore strict monitoring of blood counts is mandatory. These two patients were actually chemotherapy-naive and may have had other risk factors not discussed here.
In relation to cycle of chemotherapy, a recent report by Crawford J. et al, 14 showed that two-thirds of patients with severe neutropenia and febrile neutropenia occur in the first cycle.
This finding tallied with our results showing that majority of our febrile neutropenia cases occurred following the first cycle and another thirty percent after the second cycle (Table 1) .
Nineteen (95%) of our patients had ANC < 0.5x10 9 L and on clinical evaluation were found to be at least moderate risk and thus the use of intravenous antibiotics was justified. 7, 8 Moreover, 60% had oral mucositis with dysphagia, odynophagia and dehydration , precluding initial use of oral drugs.
Site of Infection
Unlike many text book descriptions of infections in these group of patients, we did not document a skin, respiratory and catheter site infections. This may be explained by the fact that none of our patients had indwelling catheters for feeding, urination or drug delivery. There was only one case of documented pneumonia and urinary tract infection. Not an uncommon finding, a few patients had no evidence of site of infection. This pattern could be different if larger number of patients and more variety of drugs are involved.
Choice of Antimicrobial Agent
Standard empiric antibiotics are recommended to cover the most probable infectious agents in febrile neutropenia, but we must remember that the spectrum of infectious agents varies across different regions of the world and amongst different institutions within the same region and tend to change over time. 15, 21 For us, the ideal choice of drug combination becomes more complicated by the lack of confirmation of infectious agent by laboratory test, lack of financial resources and absence of ideal environment to prevent nosocomial infectious in this very vulnerable group. Sometimes we have to resort to the combination with minimal cost but high efficiency taking into consideration the clinical state of the patient. At the time of this study period, there were no drugs to tackle suspected methicillin-resistant Staphylococcis aureus.
The most commonly recommended monotherapies include carbepenems (e.g. Imepenem/cislastin, meropenem) or extended spectrum cephalosporin's (e.g. Ceftazidime, cefipime). 16 Prior to 2005, we noted that none of our patients receiving monotherapy with carbepenems or fourth generation cephalosporin had resolution of fever. We then developed a departmental policy to treat with combination therapies only.
Recommended combination therapies include an aminoglycoside with anti-pseudomonal penicillin with or without beta lactamase inhibitor or cephalosporin with anti-pseudomonal penicillin. 16 as a general policy for us, very sick patients received gentamycin (an aminoglycoside) combinations. The dose and frequency of gentamycin depended on renal function.
Patients who could not afford meropenem, ceftazidime or ceftriaxone but when clinically stable received ciprofloxacin with amoxicillin/clavulinic acid. Metronidazole was included for gastroenteritis or where indicated. Other combinations were also given based on site of infection.
Fluconazole is the most easily accessible effective antifungal drug against oral candida and therefore our choice. Seven out of the eight patients who received fluconazole received it upfront for obvious oral candidiasis. One patient received it prophylactically as a result of persistent fever beyond day five. A multicenter randomized trial by Winston et al 17 and a meta-analysis of sixteen randomized trials published by Kanda et al 18 
Use of Granulocyte Colony Stimulating Factors
The use of GCSF was limited due to high cost. It was used upfront in one patient. Seven other patients received it for an average of three days to improve recovery rate of neutrophil and shorten duration of stay after five days of prolonged neutropenia. The American Cancer Society recommendations 2006 22 and a Cochrane analysis 23 on the subject of GCSF concluded that its use has no impact on mortality from this fatal condition but may in fact reduce morbidity and duration of hospital stay. The mean duration of fever was 4.5 days. A study from the Netherlands 24 , a high resource country reported their average as seven days.
Eighteen (90%) recovered fully from febrile neutropenia.
Our ten percent mortality rate is comparable to worldwide average mortality rate for solid tumours of eight to ten percent. 25, 26 We must be reminded that one in ten patients on anticancer medication will develop febrile neutropenia irrespective of tumour type 27 and therefore must endeavour to protect our patients from this fatal condition whilst optimising benefit from chemotherapy. This may be difficult for poorer countries, as presently GCSF is the only means of preventing dose reductions by protecting the white cell count.
28
Use of Prophylactic Antibiotics
Two important studies published in 2005 29, 30 involving a total of 2,300 patients have suggested the use of prophylactic antibiotics in severely neutropenic patients to prevent infection.
Even though the incidence and risk of mortality were influentially reduced, prophylactic antibiotic use induced resistant patterns which has public health implications and future use of these drugs if patient develops fever. 31 Gafter-Gvilli et al also published results of a meta-analysis of fifty-six trials on the effect of antibiotic resistance in quinolone prophylaxis of neutropenic patients and concluded that the risk does not outweigh the gain. 32 From our study with limited patients, our results do not support the use of prophylactic amoxillicin/clavulinic acid on cephalosporin due to low fever recovery rate in the event of febrile neutropenia. A larger study is required to explore this further in our environment.
Conclusion
Febrile neutropenia can be managed in low resource countries with comparable outcomes as developed countries in spite of several limitations. A good history and physical examination are important components of management and impacts the choice of empiric antimicrobials. Aminoglycosides are an important component of empiric combination antibiotic treatment in our setting. In the near future we need to evaluate the economics of risk of death, cost of treatment and the cost effectiveness of prophylactic G-CSF for prevention.
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